drug
depemokimab
Marketedupdated 3mo agoby $GSK GSK plc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Asthma
all catalysts(1)
Trials studying depemokimab
- phase4Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- phase3Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
- phase3Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
- phase3Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
- phase3A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
- phase3An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
- phase3Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
- phase3Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that